Split History
ADVM split history picture
Adverum Biotechnologies (ADVM) has 1 split in our ADVM split history database. The split for ADVM took place on March 21, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of ADVM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Adverum Biotechnologies conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ADVM split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adverum Biotechnologies shares, starting with a $10,000 purchase of ADVM, presented on a split-history-adjusted basis factoring in the complete ADVM split history. ADVM split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/01/2014
End date: 05/17/2024
Start price/share: $251.60
End price/share: $8.04
Dividends collected/share: $0.00
Total return: -96.80%
Average Annual Total Return: -29.63%
Starting investment: $10,000.00
Ending investment: $319.45
Years: 9.80
Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a standard of care for ocular diseases. Co.'s main product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection. According to our ADVM split history records, Adverum Biotechnologies has had 1 split.
Date Ratio
03/21/20241 for 10
ADVM is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ADXS Split History
AEMD Split History
AEZS Split History
AFAM Split History
AFFX Split History
AGEN Split History
AGLE Split History
AGN Split History
AGRX Split History
AHPI Split History

Also explore: ADVM shares outstanding history

Email EnvelopeFree ADVM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

OpGen, Inc. (OPGN)
Blue Star Foods Corp. (BSFC)
Charles & Colvard, Ltd. (CTHR)
Seelos Therapeutics, Inc. (SEEL)
Chimera Investment Corporation (CIM)
Advent Technologies Holdings, Inc. (ADN)
Telesis Bio Inc. (TBIO)
United States Lime & Minerals, Inc. (USLM)
Inspire Veterinary Partners, Inc. (IVP)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ADVM Insider Buying

ADVM Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
Wait! Don't leave yet.
Want to receive our latest research absolutely free?

Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.